Reported figures and Equlion model projections for the next 5 years.
Metric
2025 (actual)
2026
2027
2028
2029
2030
Trend
ROE
-66.59%
-157.52%
265.38%
79.15%
48.39%
34.42%
ROA
-54.2%
-84.63%
-113.87%
-120.05%
-122.66%
-122.09%
Gross Margin
16.38%
16.38%
16.38%
16.38%
16.38%
16.38%
Sector average
16.85%
17.71%
17.71%
17.71%
17.71%
17.71%
Net Margin
-395.19%
-395.85%
-396.42%
-397.05%
-397.51%
Amounts in SEK (thousands); stock price per share. Values that are missing or fail Equlion's automated data-quality checks are shown as “-”. Stock price and valuation carry no data date: they are the Equlion model's estimate for 2025. Projections are model estimates, not investment advice.
Want the full financial forecast report for NextCell Pharma AB? It covers the balance sheet, income statement and Equlion model projections.
-397.75%
Total Assets
SEK 63,916.87K
SEK 41,447.85K
SEK 44,275.36K
SEK 49,116.54K
SEK 53,761.62K
SEK 56,528.31K
Sector average
SEK 2,857,190.78K
SEK 2,900,240.60K
SEK 3,045,009.79K
SEK 3,280,286.42K
SEK 3,536,407.14K
SEK 3,762,908.71K
Net Income
-SEK 39,351.28K
-SEK 44,586.70K
-SEK 48,804.51K
-SEK 56,059.39K
-SEK 63,097.62K
-SEK 67,326.11K
Sector average
-SEK 2,851.32K
-SEK 22,027.28K
-SEK 904.69K
-SEK 7,253.84K
-SEK 3,858.45K
-SEK 1,547.00K
Valuation
SEK 92,393.25K
SEK 104,685.54K
SEK 114,588.58K
SEK 131,622.39K
SEK 148,147.50K
SEK 158,075.62K
Sector average
SEK 3,960,502.41K
SEK 5,151,301.60K
SEK 5,189,236.02K
SEK 5,317,343.69K
SEK 5,514,329.75K
SEK 5,636,782.17K
Stock Price
SEK 0.73
SEK 0.83
SEK 0.91
SEK 1.04
SEK 1.17
SEK 1.25
Sector average
SEK 57.22
SEK 48.04
SEK 48.69
SEK 50.45
SEK 52.13
SEK 53.41
NextCell Pharma AB (NXTCL.ST) Financial Forecast | Equlion
